Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $5.8 million.

  • Editas Medicine's Depreciation & Amortization (CF) fell 54.91% to $721,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 1.30%. This contributed to the annual value of $5.8 million for FY2024, which is 4.77% down from last year.
  • Latest data reveals that Editas Medicine reported Depreciation & Amortization (CF) of $5.8 million as of FY2024, which was down 4.77% from $6.1 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Depreciation & Amortization (CF) peaked at $6.3 million during FY2022, and registered a low of $4.0 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $6.1 million (2023), whereas its average is $6.1 million.
  • In the last 5 years, Editas Medicine's Depreciation & Amortization (CF) spiked by 41.34% in 2020 and then declined by 4.77% in 2024.
  • Yearly analysis of 5 years shows Editas Medicine's Depreciation & Amortization (CF) stood at $4.0 million in 2020, then increased by 27.50% to $5.1 million in 2021, then grew by 24.25% to $6.3 million in 2022, then decreased by 3.74% to $6.1 million in 2023, then fell by 4.77% to $5.8 million in 2024.